CORE
🇺🇦
make metadata, not war
Services
Services overview
Explore all CORE services
Access to raw data
API
Dataset
FastSync
Content discovery
Recommender
Discovery
OAI identifiers
OAI Resolver
Managing content
Dashboard
Bespoke contracts
Consultancy services
Support us
Support us
Membership
Sponsorship
Community governance
Advisory Board
Board of supporters
Research network
About
About us
Our mission
Team
Blog
FAQs
Contact us
Filters
25 research outputs found
Subcutaneous trastuzumab therapy for HER2-positive early breast cancer in the routine clinical practice: First interim analysis of the National Non-Interventional Study (NIS) HerSCin.
Author
Andrea Distelrath
Antonia Ruf-Doerdelmann
+6 more
Juergen Wacker
Kerstin Luedtke-Heckenkamp
Marcus Schmidt
Sabine Schmatloch
Sherko Kummel
Stella Keitel
Publication venue
'American Society of Clinical Oncology (ASCO)'
Publication date
Field of study
No full text
Crossref
ARB: Phase II window of opportunity study of short-term preoperative treatment with enzalutamide in ER-positive and triple-negative breast cancer.
Author
Alastair Mark Thompson
Anand David Purushotham
+12 more
David Barnes
Duncan A Wheatley
Javier Cortes
Kelly Mousa
Nadia Harbeck
Nigel J Bundred
Pankaj Roy
Peter Schmid
Shah-Jalal Sarker
Sherko Kummel
Stuart McINTOSH
Ulrike Nitz
Publication venue
'American Society of Clinical Oncology (ASCO)'
Publication date
Field of study
No full text
Crossref
Investigating denosumab as an add-on neoadjuvant treatment for RANK/L-positive or RANK/L-negative primary breast cancer and two different nab-paclitaxel schedules: 2x2 factorial design (GeparX)—An iterim safety analysis.
Author
Andreas Schneeweiss
Carsten Denkert
+14 more
Christian Jackisch
Claus Hanusch
Gunter Von Minckwitz
Jens Bodo Huober
Jens U. Blohmer
Manfred Hofmann
Marianne Just
Michael Untch
Oliver J Stoetzer
Pauline Wimberger
Sherko Kummel
Sibylle Loibl
Valentina Nekljudova
Valentina Vladimirova
Publication venue
'American Society of Clinical Oncology (ASCO)'
Publication date
Field of study
No full text
Crossref
Prognostic impact of 21 Gene Recurrence Score, IHC4, and central grade in high-risk HR+/HER2-early breast cancer (EBC): 5-year results of the prospective Phase III WSG PlanB trial.
Author
Aktas Bahriye
Christgen Matthias
+18 more
Clemens Michael
Gluz Oleg
Harbeck Nadia
Just Marianne
Kates Ronald E.
Krabisch Petra
Kraemer Stefan
Kreipe Hans Heinrich
Kummel Sherko
Liedtke Cornelia
Lorenz-Salehi Fatemeh
Nitz Ulrike
Nuding Benno
Reimer Toralf
Shak Steven
Stefek Andrea
Svedman Christer
Wuerstlein Rachel
Publication venue
'American Society of Clinical Oncology (ASCO)'
Publication date
01/01/2016
Field of study
No full text
Kölner UniversitätsPublikationsServer
Prospective WSG phase III PlanB trial: Final analysis of adjuvant 4xEC -> 4x doc vs. 6x docetaxel/cyclophospham ide in patients with high clinical risk and intermediate-to-high genomic risk HER2-negative, early breast cancer
Author
Aktas Bahriye
Christgen Matthias
+18 more
Clemens Michael R.
Gluz Oleg
Harbeck Nadia
Kates Ronald
Krabisch Petra
Kreipe Hans Heinrich
Kummel Sherko
Liedtke Cornelia
Lorenz-Salehi Fatemeh
Malter Wolfram
Nitz Ulrike
Nuding Benno
Pollmanns Anke
Reimer Toralf
Shak Steven
Stefek Andrea
Uleer Christoph
Wuerstlein Rachel
Publication venue
'American Society of Clinical Oncology (ASCO)'
Publication date
01/01/2017
Field of study
No full text
Kölner UniversitätsPublikationsServer
Impact of PIK3CA mutation status on immune marker response and pCR in the WSG-ADAPT HER2+/HR+ phase II trial.
Author
Aktas Bahriye
Augustin Doris
+18 more
Braun Michael Wilhelm
Christgen Matthias
de Haas Sanne
Deurloo Regula
Forstbauer Helmut
Gluz Oleg
Harbeck Nadia
Kates Ronald E.
Kleine-Tebbe Anke
Kreipe Hans Heinrich
Kummel Sherko
Liedtke Cornelia
Malter Wolfram
Nitz Ulrike
Potenberg Jochem
Schumacher Claudia
Tio Joke
Wuerstlein Rachel
Publication venue
'American Society of Clinical Oncology (ASCO)'
Publication date
01/01/2018
Field of study
No full text
Kölner UniversitätsPublikationsServer
Pathological complete response (pCR) rates after carboplatin-containing neoadjuvant chemotherapy in patients with germline BRCA (gBRCA) mutation and triple-negative breast cancer (TNBC): Results from GeparSixto.
Author
Blohmer Jens U.
Eidtmann Holger
+17 more
Fasching Peter A.
Gerber Bernd
Hahnen Eric
Hauke Jan
Jackisch Christian
Klare Peter
Kummel Sherko
Le Loibl Sibyl
Nekljudova Valentina
Paepke Stefan
Rezai Mandi
Salat Christoph
Schmutzler Rita K.
Schneeweiss Andreas
Untch Michael
Von Minckwitz Gunter
Zahm Dirk Michael
Publication venue
AMER SOC CLINICAL ONCOLOGY
Publication date
01/01/2014
Field of study
No full text
Kölner UniversitätsPublikationsServer
Survival analysis of the prospectively randomized phase III GeparSepto trial comparing neoadjuvant chemotherapy with weekly nab-paclitaxel with solvent-based paclitaxel followed by anthracycline/cyclophosphamide for patients with early breast cancer-GBG69
Author
Aktas Bahriye
Blohmer Jens Uwe
+19 more
Denkert Carsten
Fasching Peter A.
Furlanetto Jenny
Gerber Bernd
Hackmann John
Hanusch Claus
Jackisch Christian
Just Marianne
Kummel Sherko
Loibl Sibylle
Nekljudova Valentina
Rhiem Kerstin
Schem Christian
Schmatloch Sabine
Schneeweiss Andreas
Untch Michael
von Minckwitz Gunter
Warm Mathias
Wiebringhaus Hermann
Publication venue
'American Association for Cancer Research (AACR)'
Publication date
01/01/2018
Field of study
No full text
Crossref
Kölner UniversitätsPublikationsServer
RIBECCA: A phase IIIb, multi-center, open label study for women with estrogen receptor positive locally advanced or metastatic breast cancer treated with ribociclib (LEE011) in combination with letrozole—Results of the first interim analysis.
Author
Andreas Schneeweiss
Arnd Nusch
+16 more
Bernhard Heinrich
Christian M. Kurbacher
Christoph Mundhenke
Claudia Voges
Diana Lueftner
Gernot Guderian
Hans Tesch
Joerg Schubert
Martin H. Schuler
Peter A. Fasching
Petra Krabisch
Sara Brucker
Sherko Kummel
Tanja N. Fehm
Thomas Decker
Wolfgang Janni
Publication venue
'American Society of Clinical Oncology (ASCO)'
Publication date
Field of study
No full text
Crossref
Prognostic impact of androgen receptor (AR) and forkhead box A1 (FOXA1) in early HER2-negative primary breast cancer: A translational substudy of the prospective phase III WSG-PlanB-trial.
Author
Aktas Bahriye
Christgen Matthias
+18 more
Clemens Michael R.
Degenhardt Tom
Gluz Oleg
Harbeck Nadia
Heyl Volker
Just Marianne
Kates Ronald E.
Kraemer Stefan
Kreipe Hans Heinrich
Kummel Sherko
Liedtke Cornelia
Lorenz-Salehi Fatemeh
Nitz Ulrike
Nuding Benno
Reimer Toralf
Stefek Andrea
Uleer Christoph
Wuerstlein Rachel
Publication venue
'American Society of Clinical Oncology (ASCO)'
Publication date
01/01/2016
Field of study
No full text
Kölner UniversitätsPublikationsServer
1
2
3